History
Documents created during the development process.
Review proposal consultation
Background information
-
-
Crohn's disease - infliximab (review) and adalimumab: review decision - March 2011 information
-
Appendix A: Decision paper presented to the Institute's Guidance Executive
-
Appendix A: Decision paper presented to the Institute's Guidance Executive (PDF 96 KB)
-
-
Appendix A: Matrix of stakeholders
-
-
Appendix B: Proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 135 KB)
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 135 KB)
-
NICE recommends two more treatments for Crohn's disease information
-
-
2010-52 NICE recommends two more treatments for Crohn?s disease (PDF 69 KB)
Crohn's disease - infliximab (review) and adalimumab: final appraisal determination
-
Crohn's disease - infliximab (review) and adalimumab: final appraisal determination information
-
Crohn's disease - infliximab (review) and adalimumab: final appraisal determination document
-
-
Response to consultee and commentator comments and the response and comments to the website consultation on the Appraisal Consultation Document
-
-
Consultee and commentator comments on the ACD
-
Abbott
-
-
National Association for Colitis and Crohn's Disease
-
National Association for Colitis and Crohn's Disease (PDF 51 KB)
-
Royal College of Physicians & British Society of Gastroenterology
-
Royal College of Physicians & British Society of Gastroenterology (PDF 43 KB)
-
Schering Plough
-
-
Royal College of Nursing
-
-
Welsh Assembly Government (WAG)
-
-
Website responses
-
-
Department of Health
-
Crohn's disease - infliximab (review) and adalimumab: appraisal consultation
-
Crohn's disease - infliximab (review) and adalimumab: appraisal consultation
-
Crohn's disease - infliximab (review) and adalimumab: appraisal consultation document information
-
Crohn's disease - infliximab (review) and adalimumab: evaluation report
-
Consultee and commentator comments on the ACD
-
Abbot
-
-
Department of Health
-
-
Hammersmith and Fulham PCT
-
-
National Association for Colitis and Crohn's Disease
-
National Association for Colitis and Crohn's Disease (PDF 26 KB)
-
NHS - Quality Improvement Scotland
-
-
Novartis Pharmaceuticals UK
-
-
Royal College of Nursing
-
-
Royal College of Physicians & British Society of Gastroenterology 1
-
Royal College of Physicians & British Society of Gastroenterology 1 (PDF 76 KB)
-
Royal College of Physicians & British Society of Gastroenterology 2
-
Royal College of Physicians & British Society of Gastroenterology 2 (PDF 37 KB)
-
Schering Plough Ltd
-
-
Welsh Assembly Government (WAG)
-
-
Website responses
-
Crohn's disease - infliximab (review) and adalimumab: appraisal consultation
-
Crohn's disease - infliximab (review) and adalimumab: appraisal consultation
-
Crohn's disease - infliximab (review) and adalimumab: appraisal consultation document information
-
Evaluation report
-
Overview by technical lead
-
-
Crohn's disease - infliximab (review) and adalimumab: consultee and commentator comments for first ACD
-
Abbott
-
-
Schering - Plough
-
-
NACC
-
NACC 1
-
-
NACC 2
-
-
BSG
-
-
Royal College of Physicians
-
-
Department of health
-
-
NHS QIS
-
-
Welsh Assembly Government
-
-
Sally Mitton - Clinical expert
-
-
Table of web comments from first ACD
-
-
DSU report (version 2)
-
-
Crohn's disease - infliximab (review) and adalimumab: consultee and commentator responses to final DSU Report
-
Abbott
-
-
BSG and Royal College of Physicians
-
-
Department of Health
-
-
NACC
-
-
Royal College of Nursing
-
-
Schering - Plough
-
-
DSU responses to comments from consultees and commentators
-
DSU responses to comments from consultees and commentators (PDF 85 KB)
DSU specification - April 2009
-
DSU specification - April 2009
-
Crohn's disease - infliximab (review) and adalimumab: DSU report
-
Crohn's disease - infliximab (review) and adalimumab: DSU report
-
Crohn's disease - infliximab (review) and adalimumab: DSU report (PDF 61 KB)
Crohn's disease - infliximab (review) and adalimumab: decision support unit specification form
-
Crohn's disease - infliximab (review) and adalimumab: decision support unit specification form
-
Crohn's disease - infliximab (review) and adalimumab: letter to consultees and commentators regarding additional work
-
Crohn's disease - infliximab (review) and adalimumab: letter to consultees and commentators regarding additional work
-
Crohn's disease - infliximab (review) and adalimumab: appraisal consultation
-
Crohn's disease - infliximab (review) and adalimumab: appraisal consultation
-
Crohn's disease - infliximab (review) and adalimumab: appraisal consultation document information
-
Crohn's disease - infliximab (review) and adalimumab: evaluation report
-
Assessment report
-
-
Overview
-
Overview
-
-
Overview - Errata - corrected textual errors 1
-
-
Overview - Errata - corrected textual errors 2
-
-
Expert written personal statements
-
Steven
-
-
Mitton
-
-
Ghosh
-
-
Croft
-
-
Manufacturer submissions (executive summary only)
-
Schering Plough - cost-effectiveness of scheduled maintenance treatment
-
Schering Plough - cost-effectiveness of scheduled maintenance treatment (PDF 157 KB)
-
Schering Plough - appendices
-
-
Schering Plough - executive summary
-
-
Abbott Laboratories
-
-
Non-manufacturer submission
-
Royal College of Physicians
-
-
Royal College of Nursing
-
-
National Association for Colitis and Crohn's Disease (NACC)
-
National Association for Colitis and Crohn's Disease (NACC) (PDF 222 KB)
-
Consultee and commentator comments on the assessment report
-
Sanofi Aventis
-
-
Schering Plough
-
-
Royal College of Nursing
-
-
NHS Quality Improvement Scotland
-
-
National Association for Colitis and Crohn's Disease (NACC)
-
National Association for Colitis and Crohn's Disease (NACC) (PDF 22 KB)
-
Department of Health
-
-
Bedfordshire PCT
-
-
Abbott Laboratories
-
Crohn's disease - infliximab (review) and adalimumab: committee meeting
Crohn's disease - infliximab (review) and adalimumab: cancellation of committee meeting
Crohn's disease - infliximab (review), certolizumab pegol and adalimumab - Removal of certolizumab pegol letter to Consultees and Commentators
-
Crohn's disease - infliximab (review), certolizumab pegol and adalimumab - Removal of certolizumab pegol letter to Consultees and Commentators
-
Crohn's disease - infliximab (review) and adalimumab - Protocol
-
Crohn's disease - infliximab (review) and adalimumab - Protocol
-
Crohn's disease - infliximab (review) and adalimumab - Protocol (PDF 229 KB)
Crohn's disease - infliximab (review) and adalimumab: final scope
-
Crohn's disease - infliximab (review) and adalimumab: final scope
-
Crohn's disease - infliximab (review) and adalimumab: final scope (PDF 118 KB)
Crohn's disease - infliximab (review) and adalimumab : Response to comments on draft scope
-
Crohn's disease - infliximab (review) and adalimumab : Response to comments on draft scope
-
Crohn's disease - infliximab (review) and adalimumab: Response to comments on the provisional matrix
-
Crohn's disease - infliximab (review) and adalimumab: Response to comments on the provisional matrix
-
Crohn's disease - infliximab (review) and adalimumab: Draft scope
-
Crohn's disease - infliximab (review) and adalimumab: Draft scope
-
Crohn's disease - infliximab (review) and adalimumab: Draft scope (PDF 121 KB)
Crohn's disease - infliximab (review) and adalimumab: Provisional matrix of consultees and commentators
-
Crohn's disease - infliximab (review) and adalimumab: Provisional matrix of consultees and commentators
-
Crohn's disease - infliximab (review) and adalimumab: Letter to consultees and commentators
-
Crohn's disease - infliximab (review) and adalimumab: Letter to consultees and commentators
-